- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Di | Tyra Biosciences GAAP EPS of -$0.69 misses by $0.04 | 2 | Seeking Alpha | ||
| Di | Tyra Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Di | Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights | 53 | PR Newswire | - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -
- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in... ► Artikel lesen | |
| 10.06. | BofA raises Tyra Biosciences stock price target on safety outlook | 3 | Investing.com | ||
| 10.06. | BofA hebt Kursziel für Tyra Biosciences nach positiven Signalen zur Sicherheit an | 1 | Investing.com Deutsch | ||
| 04.06. | Raymond James reiterates Strong Buy on Tyra Biosciences stock amid recent weakness | 1 | Investing.com | ||
| 02.06. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | Wolfe Research initiates Tyra Biosciences stock at Peerperform | 1 | Investing.com | ||
| 13.05. | Tyra Biosciences GAAP EPS of -$0.64 | 3 | Seeking Alpha | ||
| 13.05. | Tyra Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Tyra Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.05. | Tyra Biosciences: Anleger blicken über Quartalszahlen hinaus auf entscheidende Studiendaten zu Blasenkrebs | - | Investing.com Deutsch | ||
| 22.04. | Tyra Biosciences: Board Appointment Of Habib Dable Supports Next Phase Of Growth | 1 | pulse2.com | ||
| 17.04. | Cantor Fitzgerald reiterates Tyra Biosciences stock rating | 2 | Investing.com | ||
| 17.04. | Cantor Fitzgerald bestätigt 'Overweight'-Rating für Tyra Biosciences | 2 | Investing.com Deutsch | ||
| 17.04. | Tyra Biosciences beruft Habib Dable in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 17.04. | Tyra Biosciences adds Habib Dable to board of directors | 1 | Investing.com | ||
| 17.04. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.04. | This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | 1 | Benzinga.com | ||
| 02.04. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 104,39 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 49,640 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,350 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 44,790 | +0,19 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,850 | +0,02 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,310 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| APOGEE THERAPEUTICS | 134,17 | -0,01 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| DISC MEDICINE | 77,80 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| VERA THERAPEUTICS | 29,920 | -0,10 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 61,12 | +0,02 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,910 | 0,00 % | Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note | ||
| ERASCA | 18,370 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 31,490 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 49,940 | 0,00 % | Sionna Therapeutics Aktie markiert Rekordhoch bei 51,63 USD | ||
| VERADERMICS | 107,00 | -0,21 % | Weekly Buzz: Novartis, Merck & Co. Win FDA Nod; Eli Lilly Snaps Up AtaiBeckley; Veradermics Shines On Hair Loss Data | BASEL (dpa-AFX) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and... ► Artikel lesen |
TYRA BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 32,530 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.